Answers are grounded in this paper and cite their sources.
Natural killer (NK) cells have emerged as promising candidates for adoptive immunotherapies. Their natural cytotoxic capabilities and low incidence of side-effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity, render NK cells a favorable alternative to T cells. Incorporation of a chimeric antigen receptor (CAR) has been shown to greatly enhance NK cell’s antitumor capacity. Nevertheless, CAR-NK cell therapies still face several challenges, such as low in vivo persistence, low tumor homing of the transfused cells and the effects of the immunosuppressive tumor microenvironment (TME). Genetic modifications of key cellular mediators show great potential to overcome these hurdles. While well-established viral engineering strategies are currently the most commonly used techniques, biosafety concerns, high costs, and labour-intensive protocols have encouraged innovation toward nonviral strategies. In this review, we describe recently established viral and nonviral technologies used for NK cell engineering, focusing on their respective advantages and disadvantages. In addition, we highlight the most important functional refinements and mechanistic characterizations of NK cells and genetically optimized NK cells in the context of the TME and how these advances can be progressed toward therapeutic translation.
No takes yet. Share an insight, caveat, or question.
Kluge et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: